Abstract: The application provides a non-aqueous electrolyte for a lithium ion battery, including a non-aqueous organic solvent and lithium salt, and the non-aqueous electrolyte further includes one or more selected from the compounds represented by Formula 1 and Formula 2. R1, R2, R3 and R4 are each independently selected from a substituted or unsubstituted alkyl group and ether group and unsaturated hydrocarbon group, and at least one of R1, R2, R3 and R4 is the substituted or unsubstituted unsaturated hydrocarbon group, and R5 is selected from a substituted or unsubstituted alkylene group and ether group; R6, R7 and R8 are each independently selected from a substituted or unsubstituted alkyl group and ether group and unsaturated hydrocarbon group, provided that at least one of R6, R7 and R8 is the substituted or unsubstituted unsaturated hydrocarbon group. The application also provides a lithium ion battery including the non-aqueous electrolyte.

Abstract: In order to overcome the problem of low ionic conductivity in the existing polymer solid electrolyte, the disclosure provides a solid electrolyte, comprising a polymer, a lithium salt and an additive, the additive is selected from an aprotic organic solvent with a carbon number lower than 10 and a relative dielectric constant higher than 3.6; the mass content of the lithium salt is 30%˜90%, and the mass content of the additive is 0.01%˜2%, based on the total mass of the solid electrolyte being 100%. Further provided is a polymer lithium ion battery comprising the solid electrolyte. According to the solid electrolyte of the disclosure, a trace amount of small molecule aprotic organic solvent with high dielectric constant is introduced as an additive, which can inhibit crystallization of the solid electrolyte, promote transmission of lithium ions in the electrolyte, and improve the ionic conductivity of the solid electrolyte at room temperature.

Abstract: Provided is a metal-sulfur battery, comprising a positive electrode material, a negative electrode material and an electrolyte, the positive electrode material comprises one of elemental sulfur and S-based compound; the electrolyte comprises a solvent and an electrolyte salt; and the electrolyte salt comprises one or more salts represented by structural formulas 1-3: wherein, R1 is selected from S or Se; R2 is selected from C, Si, Ge or Sn; M1 is selected from N, B, P, As, Sb or Bi; M2 is selected from Li, Na, K, Ru, Cs, Fr, Al, Mg, Zn, Be, Ca, Sr, Ba or Ra; R3 is selected from a carbon chain or an aromatic ring with part or all of hydrogen substituted by other elements or groups. The metal-sulfur battery provided by the disclosure can effectively solve the short circuit problem caused by metal dendrites on the negative electrode of existing metal-sulfur battery.

Abstract: The present invention relates to an electrolyte, an additive thereof, a secondary cell, and an application thereof. An organic electrolyte according to a first aspect of the invention comprises a salt, a phosphate ester and a fluoroether, and does not comprise a carbonate ester. The salt is a lithium salt or a sodium salt. The electrolyte according to a second aspect of the invention comprises a base electrolyte and an additive. The base electrolyte comprises a sodium salt and a flame retardant solvent. The flame retardant solvent comprises a phosphate ester and a fluoroether. The additive comprises a fluorine-containing additive. The electrolyte and the secondary cell of the present invention increase safety.

Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.

Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.

Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.

Abstract: The present invention is directed to a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.

Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.

Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.

Abstract: The invention relates to novel tomaymicine derivatives comprising a linker. It also relates to the conjugate molecules that comprise one or more of said tomaymicine derivatives covalently linked to a cell binding agent through a linking group that is present on the linker of the tomaymycin derivative. It also relates to the preparation of the tomaymicine derivatives and of the conjugate molecules.

Abstract: The present invention is directed to a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.

Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.

Abstract: The present invention is related to new tomaymycin derivatives, their process of preparation and their therapeutic uses.

Abstract: The invention relates to novel tomaymicine derivatives comprising a linker. It also relates to the conjugate molecules that comprise one or more of said tomaymicine derivatives covalently linked to a cell binding agent through a linking group that is present on the linker of the tomaymycin derivative. It also relates to the preparation of the tomaymicine derivatives and of the conjugate molecules.

Abstract: The present invention is related to new tomaymycin derivatives, their process of preparation and their therapeutic uses.